Mar 24, 2022
Dr. Jeff Burns talks with Dr. Lon Schneider about the development of ARIA in the Phase 3 EMERGE and ENGAGE trials that led to the FDA's accelerated approval of aducanumab for the treatment of Alzheimer disease.
Mar 24, 2022
Dr. Jeff Burns talks with Dr. Lon Schneider about the development of ARIA in the Phase 3 EMERGE and ENGAGE trials that led to the FDA's accelerated approval of aducanumab for the treatment of Alzheimer disease.